enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones

Michael Heffernan assumes the role of Chairman of the Board Dr. Richard Glickman to step down Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026 Initiation of BLA submission for detalimogene planned for 2H 2026 Potential FDA approval of detalimogene in 2027 BOSTON & MONTREAL — enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” […]